Advances in cardiac imaging are central to diagnosing hypertrophic cardiomyopathy, differentiating it from phenocopies like athlete's heart or cardiac amyloidosis, and guiding targeted therapies.
Advanced cardiac imaging is essential for diagnosing hypertrophic cardiomyopathy and differentiating it from phenocopies like cardiac amyloidosis and Fabry disease, which is critical for guiding specific disease-modifying therapies.
PURPOSE OF REVIEW: The aim of this study was to review imaging of myocardial hypertrophy in hypertrophic cardiomyopathy (HCM) and its phenocopies. The introduction of cardiac myosin inhibitors in HCM has emphasized the need for careful evaluation of the underlying cause of myocardial hypertrophy. RECENT FINDINGS: Advances in imaging of myocardial hypertrophy have focused on improving precision, diagnosis, and predicting prognosis. From improved assessment of myocardial mass and function, to assessing myocardial fibrosis without the use of gadolinium, imaging continues to be the primary tool in understanding myocardial hypertrophy and its downstream effects. Advances in differentiating athlete's heart from HCM are noted, and the increasing rate of diagnosis in cardiac amyloidosis using noninvasive approaches is especially highlighted due to the implications on treatment approach. Finally, recent data on Fabry disease are shared as well as differentiating other phenocopies from HCM. SUMMARY: Imaging hypertrophy in HCM and ruling out other phenocopies is central to the care of patients with HCM. This space will continue to rapidly evolve, as disease-modifying therapies are under investigation and being advanced to the clinic.
Al‐Rashdan et al. (Fri,) conducted a review in Hypertrophic cardiomyopathy and its phenocopies. Cardiac imaging was evaluated. Advances in cardiac imaging are central to diagnosing hypertrophic cardiomyopathy, differentiating it from phenocopies like athlete's heart or cardiac amyloidosis, and guiding targeted therapies.